Intermountain Precision Genomics, part of the Intermountain Health system, and Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will begin providing oncology test results that allow access to the ComboMATCH trials. ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of the… Read more »
Marianne Hamilton will never forget the day she heard the words, “it’s malignant” and the room started to spin. Knowing that breast cancer strikes one in five women in their lifetime, and because of a family history of cancer, Hamilton always imagined for her it wasn’t a question of if, but when. Even still, when… Read more »
Surgery is a common first-line treatment for prostate cancer. Out of the approximately 300,000 people who are diagnosed every year in the United States, 90,000 undergo prostatectomy, or partial or completely removal of the prostate. But for 20-50% of these patients, prostate-specific antigen, a marker of prostate cancer, persists. A new international study involving researchers and… Read more »
Register now for the 7th Annual Arizona Cord Blood Conference: “United by Our Strengths” on April 7th, 2022 (Free hybrid online/in-person event, open to the public, highly recommended for health care professionals). Join us for an informative day featuring nationally recognized experts in the field of cord blood clinical practice and research. The program will… Read more »
New treatment adds years to cancer diagnoses and quality of life during final years. Global Stem Cells Group, a global network of doctors, researchers, and students that work together to share information and advancements in the study of stem cell develop and extraction today, this week made a very strategic and important agreement with Recell… Read more »
Notifications